Table 3 Predictors of Original Site Failure
| Â | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
SHR | p | SHR | p | |
Age (≤50y vs >50y) | 0.55 (0.26–1.16) | 0.116 |  |  |
Sex (female vs male) | 0.61 (0.29–1.26) | 0.183 |  |  |
Histology (non-adenocarcinoma vs adenocarcinoma) | 0.19 (0.08–0.43) | < 0.001 | 0.19 (0.05–0.78) | 0.021 |
ECOG (0–1 vs 2) | 0.45 (0.12–1.75) | 0.250 |  |  |
Primary tumor size (< 3.5 vs ≥3.5) | 2.74 (1.28–5.87) | 0.010 | 2.45 (1.12–5.35) | 0.024 |
T stage (T1–2 vs T3–4) | 0.88 (0.42–1.85) | 0.749 |  |  |
N stage (N0 vs N1–3) | 3.13 (0.68–14.5) | 0.144 |  |  |
Number of metastatic organs (1–2 vs ≥3) | 2.44 (1.14–5.24) | 0.022 | 1.77 (0.78–4.04) | 0.175 |
Number of metastatic lesions (1–5 vs ≥6) | 4.16 (1.29–13.5) | 0.017 | 3.12 (0.77–12.7) | 0.111 |
Presence of lung metastases (No vs Yes) | 0.84 (0.33–2.10) | 0.703 |  |  |
Presence of liver metastases (No vs Yes) | 1.57 (0.06–4.39) | 0.386 |  |  |
Presence of brain metastases (No vs Yes) | 3.50 (1.62–7.54) | 0.001 | 2.31 (1.07–4.97) | 0.033 |
Presence of adrenal metastases (No vs Yes) | 1.59 (0.51–4.95) | 0.423 |  |  |
Presence of bone metastases (No vs Yes) | 1.13 (0.51–2.37) | 0.737 |  |  |
Prior lines of therapy (≥1 vs 0) | 1.02 (0.48–2.10) | 0.960 |  |  |
Prior local therapy (No vs Yes) | 1.13 (0.55–2.32) | 0.731 |  |  |
Objective response (No or Yes) | 0.84 (0.36–1.95) | 0.691 |  |  |